Antimicrobial Resistance (AMR) poses significant healthcare challenges worldwide. AMR disrupts effective treatment of infectious diseases and threatens to escalate morbidity and mortality rates if unchecked. Urinary Tract Infections (UTIs) rank as the second most prevalent bacterial diseases, with escalating rates of AMR, thereby necessitating a systematic investigation into the patterns and associated risk factors. Our research, conducted at the Urology Department at Alexandria University Hospital, aimed to decipher these patterns and predictors. This study offers critical insights that may potentially strengthen antimicrobial stewardship programs and promote rational antibiotic usage.
Our retrospective study included all patients admitted between October 2018 to October 2020, with a total of 469 patients with UTIs. The most commonly isolated bacteria were Escherichia coli and Klebsiella pneumoniae. Multidrug resistance (MDR) among patients with hospital-acquired UTIs was 67.7%, and 49.4% in patients with community-acquired UTIs. Numerous risk factors were associated with AMR, including use of antibiotics within three months, age over 60, recurrent UTIs, diabetes mellitus, and hospital-acquired UTIs. Notably, antibiotic use in the previous three months surfaced as the most significant predictor for developing drug resistance.
The consequences of continual AMR escalation are grim, with global deaths attributed to AMR projected to reach 10 million per year by 2050. As such, our research underlines the necessity for regular assessment of resistance patterns and the implementation of robust antimicrobial stewardship programs across healthcare facilities, focusing on strategic antibiotic use as pivotal in curbing future AMR increases. Our study also emphasizes the importance of investigating new biological systems or designed drugs capable of overcoming microbial resistance.
Overall, our data support the necessity for adopting a dual strategy of optimizing antimicrobial usage and intensifying exploration of new treatment models as a comprehensive response to the threat of AMR in UTIs. The future of patient care in our hospitals, and indeed globally, depends on our resilience and innovative thinking in combating the serious challenge of antimicrobial resistance.
Source: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09086-6